TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
IMRX

Immuneering Corp

Healthcare · Biotechnology

3.70$ +5.4% vs. previous close Closing price · As of: Nov 3, 2026

Ownership

Ownership Structure

Who owns Immuneering Corp (IMRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.1% of the shares are freely tradable; institutional investors hold 47.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 47.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 13.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 76.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 31.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 65Mio.

Largest Shareholders

Institutions

Institutions IMRX
Name Stake (%) Shares Change (%) Date
FMR Inc 15.00 9,704,610 +0.1 06/30/2026
BlackRock Inc 6.76 4,374,020 +190.2 06/30/2026
Sanofi 4.19 2,708,559 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.53 2,286,434 -0.1 06/30/2026
T. Rowe Price Associates, Inc. 2.99 1,936,076 +5.8 06/30/2026
Geode Capital Management, LLC 2.12 1,370,750 +114.9 06/30/2026

Funds

Funds IMRX
Name Stake (%) Shares Change (%) Date
HBM Healthcare Investments AG Ord 5.64 3,646,304 +0.0 06/30/2026
Fidelity Growth Company Fund 4.54 2,940,043 +0.0 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.51 1,623,577 +0.0 09/30/2026
iShares Russell 2000 ETF 2.20 1,422,809 -1.1 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?